pharma · Melanoma · Multiple Myeloma · RNA
Atrium Therapeutics
Atrium Therapeutics is a pharma organization headquartered in San Diego, USA. It trades on NYSE under ticker RNA. Primary therapeutic focus areas include Melanoma, Multiple Myeloma, Germ Cell Tumor, Renal Carcinoma, Acut
10578 Science Center Dr, Suite 125, San Diego, California 92121, US HQ
2026 Founded
46 Employees
Public company Type
RNA · NYSE Ticker
Company details
- Status
- Public
- HQ
- 10578 Science Center Dr, Suite 125, San Diego, California 92121, US
- Founded
- 2026
- Employees
- 46
- Programs
- 31
- Drugs
- 33
- Patents
- 37
Ropivacaine HCL
Phase 3 · small molecule · Renal Carcinoma
Ropivacaine HCL for Renal Carcinoma is a Phase 3 program (small_molecule) at Atrium Therapeutics with 1 ClinicalTrials.gov record(s).
Internal code IRB00133736
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Atrium Therapeutics
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- Renal Carcinoma
- Status
- active
- Trials
- 1